- Alexandra Schulz,
- Benedikt Ribitsch,
- Paul Christian Fuchs,
- Alexandra Lipensky,
- Jennifer Lynn Schiefer
Adv Skin Wound Care 2018 Jul;31(7):314-321
In the Department of Plastic Surgery, Hand Surgery, and Burn Center, University of Witten/Herdecke, Cologne-Merheim Medical Center, Cologne, Germany, Alexandra Schulz, MD, is a Senior Resident; Benedikt Ribitsch, MD, is a Resident; Paul Christian Fuchs, PhD, is Professor and Director; Alexandra Lipensky, MD, is a Resident; and Jennifer Lynn Schiefer, MD, is a Senior Resident. Acknowledgments: The NexoBrid product for enzymatic debridement has been approved for use in Germany and is currently an investigational product in a phase III controlled FDA trial in the United States. Dr Schulz has disclosed that she is a consultant for MediWound Ltd, although the current study was not funded by the product manufacturer. The authors have disclosed no other financial relationships related to this article. Submitted February 19, 2017; accepted in revised form August 3, 2017.
Objective: Because genital burns are rare, only limited information on treatment guidelines is available in the literature. Vital tissue should be preserved to promote spontaneous healing because reconstruction does not always lead to satisfying results. The aim of this report is to present a general overview of current, prevailing treatment for genital burns and compare this to study authors' experiences. Read More